Shenji Liu
Overview
Explore the profile of Shenji Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
137
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xie Y, Lu W, Liu S, Yang Q, Goodwin J, Anantha Sathyanarayana S, et al.
Oncotarget
. 2016 Jul;
7(30):47609-47619.
PMID: 27356744
ARF couples with TP53 in a canonical signaling pathway to activate cellular senescence for tumor suppressive function under oncogenic insults. However, the mechanisms on aberrant elevation of ARF in cancers...
2.
Lu W, Liu S, Li B, Xie Y, Adhiambo C, Yang Q, et al.
Oncotarget
. 2015 Jan;
6(2):771-88.
PMID: 25596733
Aberrant elevation of JARID1B and histone H3 lysine 4 trimethylation (H3K4me3) is frequently observed in many diseases including prostate cancer (PCa), yet the mechanisms on the regulation of JARID1B and...
3.
Wanjala J, Taylor B, Chapinski C, Hieronymus H, Wongvipat J, Chen Y, et al.
Mol Cancer Ther
. 2014 Nov;
14(1):278-88.
PMID: 25381262
Copy-number alterations (CNA) are among the most common molecular events in human prostate cancer genomes and are associated with worse prognosis. Identification of the oncogenic drivers within these CNAs is...
4.
Xie Y, Lu W, Liu S, Yang Q, Carver B, Li E, et al.
Mol Endocrinol
. 2014 Aug;
28(10):1629-39.
PMID: 25099011
Castration-resistant prostate cancer (PCa) (CRPC) is relapse after various forms of androgen ablation therapy and causes a major mortality in PCa patients, yet the mechanism remains poorly understood. Here, we...
5.
Xie Y, Liu S, Lu W, Yang Q, Williams K, Binhazim A, et al.
Mol Oncol
. 2014 Jun;
8(7):1355-64.
PMID: 24910389
SLUG represses E-cadherin to promote epithelial-mesenchymal transition (EMT) in various cancers. Mechanisms that regulate SLUG/E-cadherin pathway remain poorly understood, especially during tumorigenesis in vivo. Here we report that p19(Arf) (p14(ARF)...